Innova Captab Ltd
INNOVACAPInnova Captab Ltd's earnings have outrun its stock. EPS grew +9.9% in a year against a +9.7% price move.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (10 weeks in) while the P/E sits at the 79th percentile of its own 3-year range. Underneath, the last four quarters read improving — profit +26.7% year on year, and 90% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Innova Captab Ltd trades at ₹974, in a confirmed uptrend and 10 weeks into that stage. That is +16.7% against its own 200-day average. It sits at 95% of a 52-week range of ₹668 to ₹989. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 28 straight weeks.
Today the stock is in a confirmed uptrend — week 10 of stage 2, confirmed. At ₹974 it trades +16.7% versus its 200-day average and sits at 95% of its 52-week range (₹668–₹989).
Against the market, two honest reads. Cumulative: over the last 2.6 years the stock moved +80% while the NIFTY 500 moved +21% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 28 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Innova Captab Ltd trades at 39.7× P/E, at the pricey end of its own range (79th percentile). Its long-run median P/E is 37.4×, measured across 2.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 39.7× is at the pricey end of its own range (79th percentile), against a long-run median of 37.4× measured over 2.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +9.9% against a +9.7% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Innova Captab Ltd reads as mixed on its fundamental arc. Mixed — revenue growth is rising at +31.1% while profit growth is decelerating from its peak at +10.2% — the curves disagree, so the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +31.0% | +20.7% | +31.7% | — |
| Profit | +10.2% | +27.5% | +32.9% | — |
| EPS | +9.9% | +20.3% | −38.8% | — |
| Share price | +9.7% | — | — | — |
4-Factor Sector Score
65.1/100 — rank 3 of 14 in Pharma - API · 96% evidence confidence
Innova Captab Ltd scores 65.1 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 22.2 + 15.6 + 13.8 + 13.5 = 65.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Innova Captab Ltd reported ₹448 Cr of revenue in the Mar 26 quarter, +42.2% year on year. That is the 12th straight quarter of year-on-year growth. Over 7 years it has compounded at 24.3% a year. The last full year, FY26, came in at ₹1,630 Cr. The last four reported quarters add to ₹1,630 Cr.
FY26 revenue came in at ₹1,630 Cr (+31.0% on the year), capping 7 years at 24.3% compound. The latest quarter (Mar 26) printed ₹448 Cr, +42.2% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +30.9% growth against the decade's 24.3% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +31.1% over the last 4 quarters against +22.8%/yr over the last 8 — accelerating; TTM profit +10.2% vs +21.8%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Innova Captab Ltd's operating margin is 15.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 8 fiscal years the operating margin has ranged 11.0% to 15.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 15.0%, +0.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 11.0%–15.0%, and FY26's 15.0% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −0.6 pp year on year while gross margin went −3.3 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Innova Captab Ltd earned ₹38.0 Cr of net profit in the Mar 26 quarter, +26.7% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹141 Cr. The 7-year compound rate is 32.2%. That is 8.5% of the quarter's revenue. The same quarter a year earlier earned ₹30.0 Cr.
Mar 26 profit was ₹38.0 Cr, +26.7% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹141 Cr (+10.2%), and the 7-year compound rate is 32.2%.
Why profit moved: revenue contributed +42.2% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +10.7% vs revenue +30.9%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 90% of Innova Captab Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹117 Cr of operating cash against ₹141 Cr of profit. After ₹50.0 Cr of capital spending, ₹67.0 Cr was left as free cash.
FY26: operating cash of ₹117 Cr against reported profit of ₹141 Cr, leaving free cash of ₹67.0 Cr after ₹50.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 90% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 90%: the cash cycle tightened 17 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 8.6× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Innova Captab Ltd's cash conversion cycle runs 82 days in FY26, down from 99 days in FY21. Capital spending ran ₹739 Cr over the last 3 years. At FY26 sales of ₹1,630 Cr each day of that cycle holds about ₹4.5 Cr, so roughly ₹366 Cr sits inside the business at any moment.
FY26: debtors at 98 days, inventory at 125 days — roughly 4.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 82 days, tighter than FY21's 99.
The full loop: cash goes out to suppliers and production on day 0; stock waits 125 days to sell; customers pay about 98 days after that; and suppliers themselves are paid at 141 days — netting out to the 82-day cycle.
In money terms: at FY26 sales of ₹1,630 Cr, each day of the cycle holds about ₹4.5 Cr — so the 82-day loop keeps roughly ₹366 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹739 Cr over the last 3 fiscal years against ₹86.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹16.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Innova Captab Ltd earns a ROCE of 15% in FY26. That is up from a trough of 15% in FY25. Return on invested capital clears the cost of that capital by −1.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 8.7% net margin on 0.89× asset turns.
FY26 ROCE is 15%, recovered from a FY25 trough of 15% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 8.7% net margin × 0.89× asset turns × 1.68× balance-sheet leverage ≈ 13.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 10.5% − 12.0% = a −1.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Innova Captab Ltd carries total debt of ₹344 Cr against shareholder equity of ₹1,091 Cr as of Mar 26, a debt-to-equity of 0.32. On the annual view that ratio went from 0.95 in FY22 to 0.32 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹344 Cr against shareholder equity of ₹1,091 Cr — a debt-to-equity of 0.32. On the annual view, debt-to-equity went from 0.95 (FY22) to 0.32 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 1.3 points of Innova Captab Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 19.9% of the company. Foreign institutions moved −0.8 points over the same window, to 0.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −1.3 points over 8 quarters to 19.9%; Foreign institutions: −0.8 points over 8 quarters to 0.3%; Promoters: +0.0 points over 8 quarters to 50.9%.
🚨 Why the register moved: domestic institutions drove it (−1.3 points), alongside foreign institutions (−0.8 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Innova Captab Ltd: the Z-score reads 5.66. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 5.66 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 5.66.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Senores Pharmaceuticals LtdSENORES | 73.8/100Favorable setup75% evidence | LEADER | 32.4/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 16.4/25 ROCE 15.1% · OPM 30% 76% evidence | 9.4/20 P/E 47.6× · PEG — 15% evidence | 15.6/20 RS sector 19.5% · RS bench 44.3% · 1Y 95.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.4 + 16.4 + 9.4 + 15.6 = 73.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Wanbury LtdWANBURY | 71.2/100Favorable setup73% evidence | TURNING | 25.7/35 Revenue 16.5% · PAT 45.5% · OPM change 6 pp 71% evidence | 19.5/25 ROCE 36.6% · OPM 16% 95% evidence | 12.1/20 P/E 23.9× · PEG — 50% evidence | 13.9/20 RS sector 5.3% · RS bench 12.9% · 1Y 20.1%7 of 11 weeks ahead 70% evidence |
| Exact sum: 25.7 + 19.5 + 12.1 + 13.9 = 71.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Innova Captab Ltdthis pageINNOVACAP | 65.1/100Favorable setup96% evidence | LEADER | 22.2/35 Revenue 31.1% · PAT 10.2% · OPM change 0 pp 88% evidence | 15.6/25 ROCE 15% · OPM 15% 100% evidence | 13.8/20 P/E 39.7× · PEG 1.01 100% evidence | 13.5/20 RS sector -1.4% · RS bench 19.9% · 1Y 7.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 15.6 + 13.8 + 13.5 = 65.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 56.9/100Mixed-positive evidence81% evidence | TURNING | 15.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 18.2/25 ROCE 22.7% · OPM 21% 95% evidence | 11.2/20 P/E 32.4× · PEG — 50% evidence | 11.8/20 RS sector 0.7% · RS bench 9.7% · 1Y -12.3%10 of 10 weeks ahead 70% evidence |
| Exact sum: 15.7 + 18.2 + 11.2 + 11.8 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Fermenta Biotech LtdFERMENTA | 56.3/100Mixed-positive evidence70% evidence | TURNING | 11.4/35 Revenue 11.9% · PAT -6.6% · OPM change -10 pp 83% evidence | 18.0/25 ROCE 20.6% · OPM 16% 95% evidence | 11.0/20 P/E 23.4× · PEG — 15% evidence | 15.9/20 RS sector 15.7% · RS bench 49.3% · 1Y 33.5%3 of 7 weeks ahead 70% evidence |
| Exact sum: 11.4 + 18 + 11 + 15.9 = 56.3 · Decision use: Price leads the evidence: RS versus the benchmark is 49.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Ind-Swift Laboratories LtdINDSWFTLAB | 55.3/100Mixed-positive evidence83% evidence | BREAKING OUT | 22.3/35 Revenue 100% · PAT -80% · OPM change 19 pp 83% evidence | 6.5/25 ROCE 4.7% · OPM 12% 95% evidence | 6.5/20 P/E 39.4× · PEG — 50% evidence | 20.0/20 RS sector 39.4% · RS bench 68% · 1Y 114.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 6.5 + 6.5 + 20 = 55.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aarti Drugs LtdAARTIDRUGS | 49.3/100Mixed-negative evidence94% evidence | TURNING | 18.2/35 Revenue 10.5% · PAT 1.1% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.9% · OPM 14% 100% evidence | 13.3/20 P/E 20× · PEG 2.4 100% evidence | 7.2/20 RS sector -10.7% · RS bench 0.7% · 1Y -21.4%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.2 + 10.6 + 13.3 + 7.2 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Anuh Pharma LtdANUHPHR | 47.8/100Mixed-negative evidence77% evidence | ASLEEP | 16.6/35 Revenue 16.5% · PAT -12.8% · OPM change 1 pp 83% evidence | 11.1/25 ROCE 14.9% · OPM 10% 95% evidence | 13.1/20 P/E 21.9× · PEG — 50% evidence | 7.0/20 RS sector -5.4% · RS bench -2.9% · 1Y -20%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.6 + 11.1 + 13.1 + 7 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Beta Drugs LtdBETA | 45.6/100Mixed-negative evidence76% evidence | TURNING | 11.7/35 Revenue -11.3% · PAT -14.8% · OPM change 2 pp 95% evidence | 18.6/25 ROCE 19.2% · OPM 22% 76% evidence | 7.1/20 P/E 51× · PEG — 50% evidence | 8.2/20 RS sector -17.9% · RS bench 35.1% · 1Y 30.5%9 of 10 weeks ahead 70% evidence |
| Exact sum: 11.7 + 18.6 + 7.1 + 8.2 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Kopran LtdKOPRAN | 42.1/100Mixed-negative evidence77% evidence | TURNING | 16.6/35 Revenue 8.3% · PAT -34.2% · OPM change 4 pp 83% evidence | 9.6/25 ROCE 6.7% · OPM 14% 95% evidence | 8.1/20 P/E 35.8× · PEG — 50% evidence | 7.8/20 RS sector -17.6% · RS bench 19.4% · 1Y 10.6%11 of 11 weeks ahead 70% evidence |
| Exact sum: 16.6 + 9.6 + 8.1 + 7.8 = 42.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Gujarat Themis Biosyn LtdGUJTHEM | 39.8/100Mixed-negative evidence89% evidence | ASLEEP | 14.8/35 Revenue 8.6% · PAT -6.1% · OPM change 2 pp 88% evidence | 18.3/25 ROCE 17.9% · OPM 44% 100% evidence | 6.4/20 P/E 83.6× · PEG 2.77 65% evidence | 0.3/20 RS sector -22.1% · RS bench -4.7% · 1Y -1.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 18.3 + 6.4 + 0.3 = 39.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Themis Medicare LtdTHEMISMED | 28.7/100Adverse evidence68% evidence | BREAKING OUT | 13.0/35 Revenue -15.6% · PAT -80% · OPM change 15.7 pp 62% evidence | 2.4/25 ROCE 2.7% · OPM 4.9% 95% evidence | 8.5/20 P/E 587× · PEG — 15% evidence | 4.8/20 RS sector -17.2% · RS bench 0.9% · 1Y -10%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 2.4 + 8.5 + 4.8 = 28.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aarti Pharmalabs LtdAARTIPHARM | 27.4/100Adverse evidence90% evidence | ASLEEP | 7.3/35 Revenue -14% · PAT -31.3% · OPM change -7 pp 88% evidence | 11.3/25 ROCE 10.7% · OPM 19% 100% evidence | 3.3/20 P/E 34.2× · PEG 5.52 100% evidence | 5.5/20 RS sector -10.7% · RS bench -11.7% · 1Y -29.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 7.3 + 11.3 + 3.3 + 5.5 = 27.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Orchid Pharma LtdORCHPHARMA | 19.0/100Adverse evidence90% evidence | TURNING | 5.9/35 Revenue -11.8% · PAT -79.8% · OPM change -1 pp 88% evidence | 2.9/25 ROCE 2.6% · OPM 11% 100% evidence | 2.7/20 P/E 184× · PEG 4.09 100% evidence | 7.5/20 RS sector -19.8% · RS bench 29.8% · 1Y 38.9%11 of 11 weeks ahead 70% evidence |
| Exact sum: 5.9 + 2.9 + 2.7 + 7.5 = 19 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Innova Captab Ltd's share price today?
Innova Captab Ltd trades at ₹974, +9.7% over the past year. The company is valued at ₹5,575 Cr. The stock sits at 95% of its 52-week range of ₹668–₹989, +16.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 10 weeks in. — as of 31 July 2026.
What were Innova Captab Ltd's latest quarterly results?
Innova Captab Ltd reported revenue of ₹448 Cr and net profit of ₹38.0 Cr for the Mar 26 quarter. Revenue rose 42.2% and profit rose 26.7% year on year. Earnings per share were ₹6.65. The operating margin was 15.0%, 0.0 pp higher than a year earlier. — as of 31 July 2026.
What is Innova Captab Ltd's revenue?
Innova Captab Ltd reported revenue of ₹448 Cr in the Mar 26 quarter, +42.2% year on year. For the full FY26 fiscal year, revenue was ₹1,630 Cr (+31.0%). Over the last 7 years revenue compounded at 24.3% a year. — as of 31 July 2026.
What is Innova Captab Ltd's profit?
Innova Captab Ltd earned ₹38.0 Cr of net profit in the Mar 26 quarter, +26.7% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹141 Cr. The operating margin ran 15.0% in the latest quarter. — as of 31 July 2026.
What is Innova Captab Ltd's market cap?
Innova Captab Ltd's market capitalisation is ₹5,575 Cr at a share price of ₹974. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Innova Captab Ltd's P/E ratio?
Innova Captab Ltd trades at a P/E of 39.7×, at the 79th percentile of its own 3-year range, against a long-run median of 37.4×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Innova Captab Ltd pay a dividend?
Yes — Innova Captab Ltd's dividend payout was 8% of profit in FY26, and it recorded a payout in 1 of its last 8 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Innova Captab Ltd overvalued?
On its own history, Innova Captab Ltd looks expensive against its own history: its P/E of 39.7× sits at the 79th percentile of its 3-year range (long-run median 37.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is Innova Captab Ltd growing?
Yes — Innova Captab Ltd is growing: latest-quarter revenue +42.2% year on year, profit +26.7%, and the margin +0.0 pp at 15.0%. The 7-year compound rates are 24.3% (revenue) and 32.2% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Innova Captab Ltd performing?
Innova Captab Ltd is in a confirmed uptrend, 10 weeks in. Its latest quarter's revenue rose 42.2% and profit rose 26.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 28 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Innova Captab Ltd in?
Mixed — revenue growth is rising at +31.1% while profit growth is decelerating from its peak at +10.2% — the curves disagree, so the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +31.1% latest, profit growth +10.2% latest, eps growth +9.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Innova Captab Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 10 of stage 2), trading +16.7% versus its 200-day average and at 95% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Innova Captab Ltd beating the market?
On recent form, yes — Innova Captab Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 28 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.6 years the stock moved +80% against the NIFTY 500's +21% — ahead of the index over the full window. — as of 31 July 2026.
Will Innova Captab Ltd's share price go up?
This page publishes no price forecast for Innova Captab Ltd. What it measures instead: the share price is ₹974, the price is in a confirmed uptrend 10 weeks in. Its P/E of 39.7× sits at the 79th percentile of its own 3-year range. — as of 31 July 2026.
Who owns Innova Captab Ltd?
Promoters hold 50.9% of Innova Captab Ltd, foreign institutions 0.3%, domestic institutions 19.9% and the public 28.8% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 1.3 points over 8 quarters. — as of 31 July 2026.
Does Innova Captab Ltd have too much debt?
It is moderate — Innova Captab Ltd's debt-to-equity is 0.32, and operating profit covers the interest bill 14×. FY26 borrowings were ₹344 Cr against equity of ₹1,091 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Innova Captab Ltd's capex?
Innova Captab Ltd spent ₹739 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹50.0 Cr, with ₹16.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Innova Captab Ltd's cash flow?
Innova Captab Ltd generated ₹117 Cr of operating cash flow in FY26 and ₹67.0 Cr of free cash flow after ₹50.0 Cr of capital spending. Reported profit that year was ₹141 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Innova Captab Ltd's profit real cash?
Yes — over the last 3 fiscal years, 90% of Innova Captab Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹117 Cr against reported profit of ₹141 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
How financially safe is Innova Captab Ltd?
On the balance sheet, the Z-score reads 5.66 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 31 July 2026.
Where is Innova Captab Ltd in its business cycle?
Innova Captab Ltd's FY26 operating margin was 15.0%, against a 8-year band of 11.0%–15.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 15.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Innova Captab Ltd story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Innova Captab Ltd a stock worth studying right now?
This is not investment advice. The machine read: Innova Captab Ltd's earnings have outrun its stock. EPS grew +9.9% in a year against a +9.7% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.